相关实验视频

Updated: Jun 27, 2026

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

一种新型病毒样颗粒疫苗诱导了猪仔对deltacoronavirus的广泛免疫保护

Baotai Zhang¹, Siyuan Li², Jinzhu Zhou²

¹Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology Ministry of Agriculture, Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Nanjing, 210014, China; College of Animal Science, Guizhou University, Guiyang, 550025, China.

|June 25, 2024

概括

病毒样颗粒 (VLPs) 显示出作为猪三角型冠状病毒 (PDCoV) 疫苗候选人的希望. PDCoV VLPs成功地保护小猪免受感染,证明了它们在更广泛的冠状病毒疫苗开发方面的潜力.

科学领域:

兽医病毒学兽医病毒学
免疫学免疫学免疫学
疫苗开发疫苗开发

背景情况:

由于物种间传播,冠状病毒 (CoV) 构成重大公共卫生风险.
病毒样颗粒 (VLP) 由于其免疫原性质,为CovV疫苗开发提供了一个有前途的平台.

研究的目的:

使用尖端 (S),膜 (M) 和包膜 (E) 蛋白质,设计猪三角冠状病毒 (PDCoV) 病毒样粒子 (VLPs).
评估PDCoV VLPs在小鼠和小猪中的免疫性和保护功效.

主要方法:

由S,M和E蛋白组成的工程 PDCoV VLPs.
在小鼠中评估免疫反应,使用中和化试验和流细胞计.
接种PDCoV VLPs或非活化疫苗的孕母猪,然后用PDCoV.口服挑战小猪.

主要成果:

在小鼠中,PDCoV VLPs诱导了强大的中和抗体 (NAbs) 和细胞免疫.
由VLP免疫母猪产生的小猪在挑战后显示出高的NAb标位和显著减少的肠道损伤.
与对照组不同的是,在接种PDCoV VLPs的母猪的小猪中没有观察到腹.

结论:

PDCoV VLPs代表了PDCoV疫苗接种的潜在临床候选人.
该VLP战略可以作为开发针对其他冠状病毒的疫苗的平台.

关键词:

猪三角型冠状病毒病毒保护性免疫力保护性免疫力疫苗疫苗疫苗疫苗类似病毒的粒子.

更多相关视频

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

Author Spotlight: Exploring Cloning Techniques for Full-Length DNA Fragments

Author Spotlight: Exploring Cloning Techniques for Full-Length DNA Fragments

Published on: May 17, 2024

相关概念视频

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...